WINT - Windtree Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.187
0.000 (0.000%)
At close: 2:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.187
Open0.187
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.181 - 0.187
52 Week Range0.177 - 2.534
Volume6,003
Avg. Volume120,159
Market Cap2.62M
Beta1.04
PE Ratio (TTM)-0.05
EPS (TTM)-3.89
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.30
Trade prices are not sourced from all markets
  • Capital Cubelast month

    ETFs with exposure to Windtree Therapeutics, Inc. : September 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Windtree Therapeutics, Inc. Here are 5 ETFs with the largest exposure to WINT-US. Comparing the performance and risk of Windtree Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
    Capital Cube2 months ago

    Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Windtree Therapeutics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Windtree Therapeutics, Inc. – Aradigm Corporation, Rigel Pharmaceuticals, Inc., Idera Pharmaceuticals, Inc., Innoviva, Inc., Johnson & Johnson, Pharmaxis Ltd Sponsored ADR, AbbVie, Inc., AmerisourceBergen Corporation and Acura Pharmaceuticals, ... Read more (Read more...)

  • Windtree Therapeutics Reports Second Quarter 2017 Financial Results
    PR Newswire2 months ago

    Windtree Therapeutics Reports Second Quarter 2017 Financial Results

    WARRINGTON, Pa. , Aug. 21, 2017 /PRNewswire/ --   Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, ...

  • PR Newswire2 months ago

    Windtree Announces Initiation of Financial Restructuring Program

    WARRINGTON, Pa., Aug. 18, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has initiated a financial restructuring program intended to result in an improved capital structure, which will better enable the Company to raise the necessary additional capital to fund its AEROSURF® respiratory distress syndrome (RDS) program and further develop its pipeline of surfactant products utilizing its proprietary KL4 and aerosol device technologies. As the initial step in this program, the Company has entered into a loan agreement with Lee's Pharmaceutical (HK) Limited ("Lee's"), pursuant to which Lee's has agreed to advance up to $3.9 million that will be funded at Lee's discretion in three equal installments in August, September and October, 2017, to support AEROSURF® development activities and sustain the Windtree's operations through October 31, 2017, while the parties negotiate a share purchase agreement for Lee's to acquire a controlling interest in Windtree.

  • Windtree Therapeutics and Lee's Pharmaceutical (HK) Limited Enter Into Exclusive License and Collaboration Agreement for Development and Commercialization of KL4 Surfactant Technology Platform in Asia
    PR Newswire4 months ago

    Windtree Therapeutics and Lee's Pharmaceutical (HK) Limited Enter Into Exclusive License and Collaboration Agreement for Development and Commercialization of KL4 Surfactant Technology Platform in Asia

    WARRINGTON, Pa. and SHATIN, Hong Kong, June 12, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm", SEHK Stock Code: 0950), today announced that they have entered into an exclusive license and collaboration agreement for the development and commercialization of KL4 surfactant products in select Asian markets using Windtree's proprietary KL4 surfactant and aerosolization technologies. The agreement includes AEROSURF® as well as the non-aerosol products SURFAXIN® (approved in the U.S.) and SURFAXIN LS (an improved lyophilized formulation of SURFAXIN).  Also, Windtree has granted Lee's an exclusive license to manufacture KL4 surfactant in China for use in non-aerosol surfactant products in the licensed territory.

  • Windtree Announces Successful Completion of Enrollment in AEROSURF® Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants
    PR Newswire5 months ago

    Windtree Announces Successful Completion of Enrollment in AEROSURF® Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants

    WARRINGTON, Pa., June 1, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...

  • Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial
    PR Newswire5 months ago

    Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial

    WARRINGTON, Pa., May 22, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has been awarded $0.9 million under a previously announced Phase II Small Business Innovation Research Grant (SBIR) valued at up to $2.6 million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to support the AEROSURF® phase 2b clinical trial in respiratory distress syndrome (RDS). Windtree was awarded an initial $1.0 million under this grant in August 2016, and over the next year may be awarded up to an additional $0.7 million through the completion of the phase 2b clinical trial and one-year patient follow-up.

  • Capital Cube5 months ago

    ETFs with exposure to Windtree Therapeutics, Inc. : May 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Windtree Therapeutics, Inc. Here are 5 ETFs with the largest exposure to WINT-US. Comparing the performance and risk of Windtree Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
    Capital Cube5 months ago

    Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017

    Categories: Yahoo FinanceGet free summary analysis Windtree Therapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Windtree Therapeutics, Inc. – Aradigm Corporation, Rigel Pharmaceuticals, Inc., Idera Pharmaceuticals, Inc., Innoviva, Inc., Johnson & Johnson, AbbVie, Inc., AmerisourceBergen Corporation and Acura Pharmaceuticals, Inc. (ARDM-US, RIGL-US, IDRA-US, ... Read more (Read more...)

  • Windtree Therapeutics Reports First Quarter 2017 Financial Results and Provides Key Business Updates
    PR Newswire5 months ago

    Windtree Therapeutics Reports First Quarter 2017 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa., May 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...

  • Windtree Receives Notice of Delisting from NASDAQ
    PR Newswire5 months ago

    Windtree Receives Notice of Delisting from NASDAQ

    WARRINGTON, Pa., May 3, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...

  • Accesswire6 months ago

    Windtree Therapeutics and Tonix Pharmaceuticals on the Rise after FDA Clinical Trial News

    NEW YORK, NY / ACCESSWIRE / April 12, 2017 / Windtree Therapeutics advanced 20.16% to close at $1.49 in Tuesday's trading session. The stock traded between $1.25 and $1.66 on a volume of 3.6 million shares ...

  • Windtree Announces Successful Completion of Second and Final AEROSURF® Phase 2b Clinical Trial Interim Safety Review
    PR Newswire6 months ago

    Windtree Announces Successful Completion of Second and Final AEROSURF® Phase 2b Clinical Trial Interim Safety Review

    WARRINGTON, Pa., April 11, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that the AEROSURF® (lucinactant for inhalation) phase 2b independent Data Safety Monitoring Board (DSMB) has completed its second and final interim safety review and has recommended continuing the trial without modification. The final DSMB interim review was convened following achievement in mid-March 2017 of a pre-specified patient enrollment milestone.  In addition, the Company reaffirms its plan to announce top-line results from the AEROSURF phase 2b clinical trial in mid-year 2017.

  • Capital Cube6 months ago

    ETFs with exposure to Windtree Therapeutics, Inc. : April 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Windtree Therapeutics, Inc. Here are 5 ETFs with the largest exposure to WINT-US. Comparing the performance and risk of Windtree Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017
    Capital Cube6 months ago

    Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017

    Categories: Yahoo FinanceGet free summary analysis Windtree Therapeutics, Inc. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 0.90 million, Net Earnings of USD -6.60 million. Gross margins widened from 86.87% to 93.78% compared to the same period last year, operating (EBITDA) margins now -701.33% from -1,480.15%. Change in operating ... Read more (Read more...)

  • Windtree Therapeutics Reports Fourth Quarter 2016 Financial Results and Provides Key Business Updates
    PR Newswire7 months ago

    Windtree Therapeutics Reports Fourth Quarter 2016 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa., March 31, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, ...

  • PR Newswire8 months ago

    Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation and Improves Survival in a High-Pathogen Avian Influenza Preclinical Study

    WARRINGTON, Pa., Feb. 16, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focusing on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that data from a preclinical influenza study showed that aerosolized KL4 surfactant reduced lung inflammation and improved overall survival in a well-established preclinical animal model. The Company believes that these preclinical data add to a growing body of evidence that supports the role of KL4 surfactant as a potential medical intervention to reduce morbidity and mortality associated with both seasonal and pandemic influenza pneumonia. "While we remain focused on the rigorous and timely execution of the AEROSURF® phase 2 clinical program in premature infants with respiratory distress syndrome (RDS), we are encouraged by the results of this study in influenza as there is significant unmet need to protect the lungs in patients with severe influenza pneumonia," commented Craig Fraser, President and Chief Executive Officer.

  • PR Newswire8 months ago

    Windtree Therapeutics Completes $10.5 Million Private Offering

    WARRINGTON, Pa., Feb. 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has completed a $10.5 million private placement of convertible preferred stock units and now expects that it has sufficient capital to fund its operations through the AEROSURF® phase 2b clinical trial data release in mid-2017. Windtree has received gross proceeds of approximately $10.5 million (including approximately $1.6 million in non-cash consideration in the form of a reduction in future payments of current development services expenses) from the sale of 7,049 Series A Convertible Preferred Stock Units at a purchase price per unit of $1,495.  Each unit consists of one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of the Company's common stock, and 1,000 Series A-1 seven-year warrants to purchase one share of the Company's common stock at an exercise price of $1.37.

  • PR Newswire8 months ago

    Windtree Therapeutics to Host a Conference Call and Webcast at 8:00 AM on Thursday, February 16, 2017 to Provide Clinical and Financial Updates

    WARRINGTON, Pa., Feb. 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will ...

  • Capital Cube9 months ago

    ETFs with exposure to Windtree Therapeutics, Inc. : January 3, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Windtree Therapeutics, Inc. Here are 5 ETFs with the largest exposure to WINT-US. Comparing the performance and risk of Windtree Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Is Windtree Therapeutics Inc (WINT) Going to Burn These Hedge Funds?
    Insider Monkey10 months ago

    Is Windtree Therapeutics Inc (WINT) Going to Burn These Hedge Funds?

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • PR Newswire11 months ago

    Windtree Therapeutics Announces Upcoming Presentations at Hot Topics in Neonatology

    WARRINGTON, Pa., Dec. 1, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...

  • PR Newswire11 months ago

    Windtree Therapeutics' AEROSURF® (lucinactant for inhalation) Phase 2a Data Presented at the 2016 International Congress of Union of European Neonatal and Perinatal Societies

    WARRINGTON, Pa., Nov. 28, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced the Company's previously released AEROSURF® (lucinactant for inhalation) phase 2a data was presented at the 6th International Congress of European Neonatal and Perinatal Societies (UENPS) held in Valencia, Spain by Jan Mazela, M.D., PhD, Poznan University of Medical Sciences. The data demonstrate that AEROSURF administered non-invasively via nasal continuous positive airway pressure (nCPAP) in premature infants 29-34 weeks gestational age (GA) with respiratory distress syndrome (RDS) was generally safe and well tolerated and may be reducing the incidence of nCPAP failure (the need for invasive intubation and delayed surfactant therapy).

  • PR Newswire11 months ago

    Windtree Therapeutics to Present at Stifel 2016 Healthcare Conference

    WARRINGTON, Pa., Nov. 8, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that Craig Frasier, President and Chief Executive Officer, will present at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York.  The presentation is scheduled for Tuesday, November 15, 2016 at 8:45 am ET. Windtree Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. Windtree's proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant.

  • PR Newswire11 months ago

    Windtree Therapeutics Preclinical Study Results Show Potential for KL4 Surfactant as Possible Medical Countermeasure to Radiation Exposure

    WARRINGTON, Pa., Nov. 3, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that recently presented preclinical data at the 62nd Radiation Research Society Annual Meeting suggest that KL4 surfactant could potentially be an effective medical countermeasure to mitigate acute and chronic/late-phase radiation-induced lung injury (pneumonopathy) due to exposure from a nuclear accident or act of terrorism. The Company believes that, as a possible additional application, KL4 surfactant may also mitigate radiation pneumonopathy associated with cancer radiation therapy.